Chardan Capital Markets resumed coverage on uniQure with a new price target
$QURE
Biotechnology: Pharmaceutical Preparations
Health Care
Chardan Capital Markets resumed coverage of uniQure with a rating of Buy and set a new price target of $38.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/1/2025 | $38.00 | Buy | Chardan Capital Markets |
| 12/10/2024 | Outperform → Strong Buy | Raymond James | |
| 10/10/2024 | $20.00 | Outperform | Raymond James |
| 2/29/2024 | $8.00 | Buy → Neutral | Goldman |
| 12/19/2023 | $52.00 → $10.00 | Buy → Neutral | Mizuho |
| 3/17/2022 | $40.00 | Neutral → Buy | UBS |
| 12/17/2021 | $75.00 → $58.00 | Strong Buy → Outperform | Raymond James |
| 10/27/2021 | $66.00 | Outperform | William Blair |